Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

2 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteins that interact with FGD5 in MDA-MB-231

ABSTRACT: To examine the presence of the proteins that interact with FGD5 in triple negative breast cancer cell line

ORGANISM(S): Homo Sapiens

SUBMITTER: Zhuo-Wei Hu

PROVIDER: PXD024266 | iProX | Fri Feb 19 00:00:00 GMT 2021

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Publications

Faciogenital Dysplasia 5 supports cancer stem cell traits in basal-like breast cancer by enhancing EGFR stability.

Li Ke K Zhang Ting-Ting TT Zhao Chen-Xi CX Wang Feng F Cui Bing B Yang Zhao-Na ZN Lv Xiao-Xi XX Yeerjiang Zaiwuli Z Yuan Yu-Fen YF Yu Jin-Mei JM Wang Zhen-He ZH Zhang Xiao-Wei XW Yu Jiao-Jiao JJ Liu Shan-Shan SS Shang Shuang S Huang Bo B Hua Fang F Hu Zhuo-Wei ZW

Science translational medicine 20210301 586

Most basal-like breast cancers (BLBCs) are triple-negative breast cancers (TNBCs), which have the worst prognosis and distant metastasis-free survival among breast cancer subtypes. Now, no targeted therapies are available for patients with BLBC due to the lack of reliable and effective molecular targets. Here, we performed the BLBC tissue microarray-based immunohistochemical analysis and showed that Faciogenital Dysplasia 5 (FGD5) abundance is associated with poor prognosis in BLBCs. <i>FGD5</i> ...[more]

PMID: 33762435

Similar Datasets

Untargeted metabolomics of breast cell lines in the presence or the absence of CtBP inhibitors

Project description:Experiments to test the effect of CtBP2 inhibition on metabolism of breast cell lines. In particular, experiment 1 involves comparison between a normal breast cell line (MCF102A) and a triple-negative breast cancer cell line (MDA-MB231). Experiment 2 is a study between MDA-MB231 silenced for CtBP2 by stable RNA interference (shCtBP2 cells) compared to scramble (shCTRL cells). Experiment 3 is a comparison between a normal breast cell line (MCF102A) and a triple-negative breast cancer cell line (MDA-MB231)in the presence of the absence of small-molecule CtBP inhibitors: HIPP (400 μM) or P4 (300 μM)for 48 hours.

2021-08-31 | ST001941 | MetabolomicsWorkbench

LINC00461 binding protein in triple negative breast cancer

Project description:Using CHIRP-MS method to detect LINC00461 binding protein in MDA-MB-231 cell line of triple negative breast cancer

2023-04-04 | PXD041363 | iProX

Expression data from DKAT breast cancer cell line pre- and post-EMT

2012-06-01 | GSE33146 | GEO

Expression data from DKAT and other breast cancer cell lines under baseline growth conditions

Project description:The DKAT cell line is a novel model of triple-negative breast cancer that was isolated from the pleural effusion of a 35 year-old caucasian woman with triple-negative breast cancer. We used microarrays to look at gene expression in the DKAT cell line compared to several other commonly-used breast cancer cell lines as well as a previously published data set in order to determine the molecular subtype of the DKAT cell line.

2012-06-01 | GSE33145 | GEO

Expression data from DKAT breast cancer cell line pre- and post-EMT

Project description:The DKAT cell line is a novel model of triple-negative breast cancer that was isolated from the pleural effusion of a 35 year-old caucasian woman with triple-negative breast cancer. When cultured in serum-free media (MEGM, Lonza) this cell line exhibits an epithelial morphology and gene expression pattern. However, when cultured in the presence of serum (SCGM, Lonza) it undergoes a reversible EMT. We used microarrays to look at gene expression changes in the DKAT cell line when cultured in Mammary Epithelial Growth Media (MEGM, where DKAT cells have an epithelial morphology) vs Stromal Cell Growth Media (SCGM, where DKAT cells have a mesenchymal morphology). DKAT breast cancer cells (passage 10) grown in MEGM (Lonza) were split and cultured in T75 flasks in either in MEGM or SCGM for 14 days. RNA was isolated using Qiagen RNeasy kit and hybridization on Affymetrix microarrays was performed. Three separate cDNA reactions were performed and these were run as technical replicates.

2012-05-31 | E-GEOD-33146 | biostudies-arrayexpress

Effect of AKTIP depletion in breast cancer cells

Project description:Copy number loss of AKTIP gene is frequently observed in breast cancer particularly luminal breast cancer. To determine the alterations in transcriptome upon AKTIP loss in luminal breast cancer cell line MCF7 and triple negative breast cancer cell line SKBR3, RNAseq of cells transfected with AKTIP siRNA was performed.

2022-08-19 | GSE209693 | GEO

RNA-seq in Hs578T cells stimulated with TGF-β

Project description:Transforming growth factor-β (TGF-β) comprises a key component in the tumor microenvironment. It is reported that TGF-β can be pro-tumorigenic or anti-tumorigenic depending on various contexts. Some of the triple negative breast cancers highly express TGF-β, but pro-tumorigenic function of TGF-β in triple negative breast cancer cells is not fully known. Therefore, we analyzed genome-wide gene expression changes after stimulation with TGF-β in a triple negative breast cancer cell line, Hs578T cells.

2020-12-24 | GSE152414 | GEO

Discrete Adaptive Responses to MEK Inhibitor In Subpopulations of Triple-Negative Breast Cancer [WES]

Project description:We report the genetic similarity of epithelial and mesenchymal subpopulations isolated from a triple-negative breast cancer cell line.

2021-11-10 | GSE138797 | GEO

Discrete Adaptive Responses to MEK Inhibitor In Subpopulations of Triple-Negative Breast Cancer [FAIRE-seq]

Project description:We report the chromatin accessibility of epithelial and mesenchymal subpopulations isolated from a triple-negative breast cancer cell line.

2021-11-10 | GSE138796 | GEO

b1-integrin binding and lysosome targeting aptamer homes to triple-negative breast cancer in mice

Project description:Targeted therapies for triple-negative breast cancer have increased the number of available treatment options for patients. However, an optimal treatment strategy is still an unmet medical need due to the lack of targetable biomarkers and tumour heterogeneity. Aptamers have high selectivity and specificity towards target proteins. Lower molecular weight, increased stability, less immunogenicity, and rapid tissue uptake make aptamers an attractive alternative to antibodies. Attempts to develop aptamer therapeutics have shown difficulties translating in vitro results to in vivo. Aptamer GreenB1 exhibits selectivity to triple-negative MDA-MB-231 human breast cancer cell line in vitro compared to estrogen, progesterone, and glucocorticoid receptor-expressing MCF-7 human breast cancer cell line. The aptamer is rapidly internalised into cells and trafficked to lysosomes. Here, we identify 1-integrin as the target protein for GreenB1 using proximity labelling and mass spectrometry proteomics. GreenB1 homes preferentially to the tumour in the 4T1 triple-negative breast cancer mice model in vivo.

2023-08-24 | PXD034982 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data